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 Women of child-bearing age who are HCV positive undergo
premature ovarian senescence.
 Such women have fewer live births, and higher rates of
miscarriage and gestational diabetes.
 Total fertility rate in women who are HCV positive vs. the
general population is 0.7 vs. 1.37.
 Miscarriage rate is significantly reduced by successful HCV
treatment.
 Antivirals should be tested for their effects on other adverse
pregnancy outcomes.Aimilia Karampatou, XueHa,
Loreta A. Kondili, ..., YanjunBao,
Yuri SanchezGonzalez,Erica Villa
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Lay summary
Most new cases of HCV infection are
among people who inject drugs, many of
whom are young women in their child-
bearing years. Women of reproductive
age who are HCV+ display markers of
ovarian senescence. This is associated
with an increased burden in terms of
infertility and adverse pregnancy out-
comes, including stillbirth, miscarriage,Viral Hepatitisfewer live births, and gestational diabetes.
Early viral suppression with therapy is
likely to mitigate these risks.s.org/licenses/by-nc-nd/4.0/). J. Hepatol. 2018, 68, 33–41
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Background & Aims: Premenopausal women who are HCV pos-
itive (HCV+) have failing ovarian function, which is likely to
impact their fertility. Thus, we investigated the reproductive
history, risk of infertility, and pregnancy outcomes in women
of childbearing age who were HCV+.
Methods: Three different groups were studied: (1) Clinical
cohort: 100 women who were HCV+ and also had chronic liver
disease (CLD), age matched with 50 women who were HBV+
with CLD and with 100 healthy women; all women were
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consecutively observed in three gastroenterology units in hospi-
tals in Italy; (2) 1,998 women who were HCV+ and enrolled in
the Italian Platform for the Study of Viral Hepatitis Therapies
(PITER); (3) 6,085 women, who were mono-infected with HCV,
and 20,415 women, who were HCV, from a large de-
identified insurance database from the USA. Measurements:
total fertility rate (TFR) defined as the average number of
children that a woman would bear during her lifetime. To
define the reproductive stage of each participant, levels of
anti-Müllerian hormone (AMH) and 17b-estradiol were
measured.
Results: Clinical cohort: women who were either HCV+ or HBV+
had similar CLD severity and age at first pregnancy. Based on a
multivariate analysis, women who were HCV+ had a higher risk
of miscarriage than those who were HBV+ (odds ratio [OR]
6,905; 95% CI 1.771–26.926). Among women who were HCV+,
incidence of miscarriage was correlated with median AMH level
(1.0 ng/ml). Achieving a sustained virologic response (SVR) after
antiviral treatment reduced the risk of miscarriage (OR 0.255;
95% CI 0.090–0.723). In the PITER-HCV cohort, miscarriage
occurred in 42.0% of women (44.6% had multiple miscarriages).
TFR for women who were HCV+ and between 15 and 49 years of
age was 0.7 vs. 1.37 of Italian population of the same age range.
In the US cohort: compared with women who were HCV,
women who were HCV+ positive were significantly more likely
to have infertility (OR 2.439; 95% CI 2.130–2.794), premature
birth (OR 1.34; 95% CI 1.060–1.690), gestational diabetes (OR
1.24; 95% CI 1.020–1.510), and pre-eclampsia (OR 1.206; 95%
CI 0.935–1.556), and were less likely to have a live birth (OR
0.754; 95% CI 0.622–0.913).
Conclusions: Ovarian senescence in women of childbearing age
who are HCV+ is associated with a lower chance of live birth,
greater risk of infertility, gestational diabetes, pre-eclampsia
and miscarriage. Such risks could be positively influenced by
successful HCV cure.018 vol. 68 j 33–41
Lay summary:Most new cases of HCV infection are among peo-
ple who inject drugs, many of whom are young women in their
childbearing years. Women of reproductive age who are HCV+
display markers of ovarian senescence. This is associated with
an increased burden in terms of infertility and adverse preg-
nancy outcomes, including stillbirth, miscarriage, fewer live
births, and gestational diabetes. Early viral suppression with
therapy is likely to mitigate these risks.
 2017 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Menopause represents a critical event in a woman’s life. Rapid
loss of oestrogen and of its protective anti-inflammatory effects
leads to a series of biological events characterised by a shift
from a non-inflamed to an inflammation-prone environment.
These changes translate into systemic symptoms, such as joint
pain, metabolic syndrome, and others. In women with HCV,
menopause has direct effects on the liver, which include faster
progression of fibrosis and marked resistance to interferon
(IFN)-based antiviral therapy.1–3 Prolonged periods of hormone
replacement therapy (HRT) appear to be associated with a lower
stage of fibrosis1,4 and improved response to antiviral therapy,
at least in the Japanese population.5
Previous data indicated that, at premenopause, women who
were HCV+ already had menopausal levels of anti-Müllerian
hormone (AMH), an accurate marker of ovarian reserve, sug-
gesting possible consequences for reproductive function.3,6–8
There was an initial decline in, followed by stabilisation of,
the prevalence of HCV from 2006 onwards.9 However, in some,
mostly resource-rich, settings, its prevalence is now increas-
ing.10 Most new HCV cases are among people who inject drugs,
many of whom are young women in their childbearing years.11
December 2015. In total, 100 women with HCV+ CLD were
matched by age in a 2:1 ratio with 50 women with HBV+ CLD,
as well as in a 1:1 ratio with 100 healthy women without liver
disease (control group). None of the women enrolled had a his-
tory of drug abuse or HIV co-infection. All patients were regu-
larly followed up as outpatients. Coverage by the Italian
National Health System was active for all women, regardless
of whether they were employed. Women were defined as being
of reproductive age if they had regular menses.
As external control groups to assess the effect of HCV infec-
tion on infertility and pregnancy outcomes, data from the Italian
Platform for the Study of Viral Hepatitis Therapies (PITER) and
from a large de-identified insurance database in the USA were
used. The PITER-HCV cohort is a structured collaboration
between the Italian National Institute of Public Health, the Ital-
ian Society for the Study of the Liver, the Italian Society for
Infectious Diseases, and their affiliated clinical centres.19 The
ad hoc web-based platform, which is certified to international
standards, includes demographic, biochemical, clinical, and
virological data, as well as specific items regarding a woman’s
reproductive history (i.e. age of menarche, gravity, parity, and
miscarriage). The proportion of women in the study who could
have had drug involvement was evaluated by determining the
number of women with an opioid-dependency code, which
was found to be <6%. The US de-identified insurance database
contains patient-level medical, prescription, and laboratory data
from between 2000 and 2015. Women aged 18–45 years who
had had one or more medical claims with an ICD-9 diagnosis
code for HCV were matched with women who were HCV in
a 1:3 ratio for the analysis of infertility and in a 1:10 ratio for
the analysis of pregnancy outcomes on the basis of age, census
region, and index year.
In the infertility analysis, women co-infected with HIV/HCV
were added as a third comparison arm.
Research Article Viral HepatitisAlthough it appears that women clear HCV infection more easily
than men, they undergo reinfection at a similar rate.12 Given
that HCV infection does not impact a woman’s desire to bear
a child,13 it is important to evaluate the effects of this disease
on reproductive function. Although there are reports of several
different health issues (such as low birth weight, prematurity,
and need for intensive care at birth) in infants born to women
who are HCV positive,14,15 only a few studies have evaluated
the risk of miscarriage or of stillbirth in such women, with con-
trasting results.16–18 While a study from Iraq suggested the pos-
sibility of higher miscarriage rate in women who were HCV+ vs.
those who were HCV,16 other studies did not report such a
correlation.17,18
Therefore, the objective of the present study was to investi-
gate ovarian function in women of childbearing age who were
HCV+ and to relate these findings with the women’s reproduc-
tive history, risk of infertility, and pregnancy outcomes, includ-
ing premature birth, live birth, still birth, gestational diabetes,
pre-eclampsia, and miscarriage.
Materials and methods
Patients
From July 2011 to March 2014, women of childbearing age with
chronic liver disease (CLD) were prospectively enrolled at the
Gastroenterology Units of the University Hospitals of Modena,
Turin, and Naples (Table 1). Follow-up was continued until34 Journal of HepatologyThe study was approved by the Ethical Committee of the
Azienda Ospedaliero-Universitaria di Modena and conducted
in accordance with provisions of the Declaration of Helsinki
and Good Clinical Practice guidelines (ClinicalTrials.gov identi-
fier: NCT01402583; NCT01945008).
Clinical and laboratory assessments
Age, reproductive status, and serum levels of AMHwere collected
for the three clinical cohorts. For the HCV+ and HBV+ groups,
virus genotype, presumed duration of infection, bodymass index
(BMI), oestrogen level, insulin-like growth factor-1 (IGF-1) level,
presence of steatosis on ultrasound, histologic features, antiviral
treatment and response, lifestyle habits (e.g. smoking and alcohol
consumption before and during pregnancy), parity, age at first
full-term pregnancy, and occurrence and number of spontaneous
abortions were also registered. Women with a history of hor-
monal manipulation, including hormone treatment for preg-
nancy support, were excluded from the study.
Liver biopsy and assessment of liver stiffness were per-
formed for women who were HCV+ or HBV+ at enrolment in
the study. A single pathologist (LM) reviewed all biopsies
according to previously defined criteria.20 Steatosis was classi-
fied as absent, mild (<5%), moderate (5–20%), or severe (>20%).
Liver stiffness was measured by transient elastography. HCV
RNA and HBV DNA were quantified by the Abbott RealTime
HCV and HBV assay, respectively (Abbott Molecular Inc., Des
Plaines, IL, USA). HCV genotyping was performed by the
INNO-LiPA II assay (Innogenetics, Gent, Belgium).2018 vol. 68 j 33–41
Table 1. Baseline characteristics of study participants with liver disease.
Characteristic HCV+ group
(n = 100)
HBV+ group
(n = 50)
p value
Age (yr)a 37.2 ± 8.5 35.1 ± 8.0 0.209
Duration of HCV infection (yr)a 12 ± 7 12 ± 8 0.972
Maternal smoking habits [n (%)]b
Never smoked 55 (55) 26 (52) 0.932
Former smoker 35 (35) 19 (38)
Current smoker 10 (10) 5 (10)
Alcohol consumption [n (%)]b
No 90 (90) 44 (88) 0.708
Yes 10 (10) 6 (12)
Employment status [n (%)]b
Employed 92 (92) 47 (94) 0.657
Unemployed 8 (8) 3 (6)
Platelet count (103/mm3)a 219 ± 70 202 ± 65 0.144
Alanine aminotransferase (IU/L)a 79 ± 30 89 ± 65 0.305
Gamma-glutamyl transferase (IU/L)a 35 ± 21 29 ± 22 0.113
Cholesterol (mg/dl)a 179 ± 50 189 ± 45 0.219
85 ± 55 0.105
77 ± 54 0.148
80 ± 25 0.233
JOURNAL 
OF HEPATOLOGYTriglyceride (mg/dl)a 99 ± 35
Ferritin (ng/ml)a 89 ± 30
Blood glucose (mg/dl)a 75 ± 22lated as appropriate. Multiple logistic regression models were
used to assess the relationship between risk of miscarriage
and the demographic, metabolic, and histological characteristics
of a combined group of women with HBV or HCV and controls,
and of only those women who were HCV+. The following base-
line variables were considered for univariate analysis: age, etiol-
ogy, grade and/or stage of disease, liver stiffness, steatosis
(absent vs. present), and AMH levels. In the HCV cohort, geno-
HOMAa 1.7 ± 1.5 1.5 ± 1.0 0.715
Mean BMI (kg/m2)a 23.6 ± 5.0 23.2 ± 4.6 0.637
n.a. -
n.a. -
0/50 -
196.000 ± 565.060 -
5.2 ± 0.5 0.001
2.4 ± 1.1 0.043
10 (20) 0.014
5.7 ± 2.0 0.468Hormone assays
Serum AMH levels were assessed by an ELISA (AMH Gen II
ELISA; Beckman Coulter, Inc., Brea, CA, USA). The sensitivity
of the assay was 0.08 ng/ml, with linearity up to 22.5 ng/
ml. Intra- and interassay coefficients of variation were <5%
and <7%, respectively. 17b-Oestradiol levels were measured
by chemiluminescent microparticle immunoassay (CMIA)
using commercially available kits and the c4000 Architect
system (Abbott Diagnostic Division, Abbott Laboratories,
Abbott Park, IL, USA). Oestradiol was additionally quantified
by the Abbott Architect Estradiol Assay 200 (2004 revision)
one-step CMIA. The assay sensitivity was <10 pg/ml, with
intra- and interassay coefficients of variation of 5.6% and
4.9%, respectively. Serum IGF-1 levels were measured by
immunoassay (Quantikinine; R&D Systems, Minneapolis, MN,
USA). The sensitivity of the assay was 0.007–0.056 ng/ml.
Assay procedures were performed in accordance with the
manufacturers’ instructions.
HCV genotype 1/2/3/4 (n)b 56/15/21/8
HCV viral load (IU/ml  103) 1.992 ± 3.900
HBeAg/anti-HBe status n.a.
HBV DNA (IU/ml) n.a.
Liver histologya
Grade of inflammation 3.6 ± 1.5
Stage 1.8 ± 1.3
Presence of steatosis [n (%)]b 40 (40)
Stiffness (kPa)a 6.0 ± 3.0
Data are reported as the mean ± SD, unless otherwise noted.
NA, not available; BMI, body mass index.
a Student’s t test for independent samples.
b Chi-square test.Statistical analysis
Continuous variables (mean ± SD) were compared using either
the Student’s t test for independent samples or the nonparamet-
ric Mann–Whitney U test as appropriate. Categorical variables
were summarised as frequency and percentage and compared
using the Chi-square test. The Pearson correlation test was used
to assess the relationship between hormonal levels and selected
clinical parameters. Odds ratios (ORs) and 95% CIs were calcu-Journal of Hepatologytype and viral load were also considered in the model. In the
US cohort, adjusted ORs for rates of infertility associated with
HCV or HIV/HCV co-infection were estimated using logistic
regressions adjusting for age, region, year of index date, types
of health plan, and co-morbidities. Similarly, ORs were calcu-
lated for the association of HCV infection with pregnancy out-
comes, including rates of premature birth, live birth, still birth,
gestational diabetes, pre-eclampsia, and miscarriage.
Total fertility rate (TFR) was defined as the average number
of children that a woman would bear during her lifetime. In
the PITER-HCV cohort, TFR was calculated by dividing the gen-
eral fertility rate by 1,000. For comparison, data from the data-
base of National Institute of Statistics of Italy (Istat) for the year
2014 were used.21
Variables with p <0.10 in univariate analysis were included
in the final multivariate model. In the statistical models, depen-
dent variables were coded as 1 (present) or 0 (absent). The IBM
SPSS Statistics, version 20 (IBM Corp., Armonk, NY, USA) was
used for analysis.2018 vol. 68 j 33–41 35
+;
Research Article Viral HepatitisFor further details regarding the materials used, please refer
to the CTAT table and supplementary information.
Results
Demographic characteristics of the HCV+ and HBV+ groups are
summarized in Table 1. No significant difference in age was
observed among the HCV+, HBV+, and control groups (mean
age of control group: 38.4 ± 5.9 yr). No significant difference
was present in lifestyle habits (cigarette smoking or alcohol
consumption) or in rate of employment between women who
were HCV+ or HBV+. Grade and stage were slightly higher in
the HBV + compared with the HCV+ group (p = 0.043). Women
who were HCV+ had a higher prevalence of steatosis. Liver stiff-
ness was not significantly different between the two groups
Table 2. Hormonal and reproductive characteristics of study participants.
Characteristic HCV+ group (n =
100)
HBV
AMH, all women (ng/ml)a 1.8 ± 2.0
AMH, 20–30 yr (ng/ml)a 2.3 ± 2.1
AMH <0.16 ng/ml [n (%)]a 34 (34)
Estradiol (ng/ml)a 77 ± 58
IGF-1 (ng/ml)a 110 ± 58
Parity, n (%)a 52 (52)
Age at first pregnancy (yr)a 30 ± 6
Occurrence of miscarriage [n (%)]b 46 (46)
N. women with multiple miscarriages, n
(%)b
8 (8)
Data are reported as the mean ± SD, unless otherwise noted.
NA, not applicable. AMH, anti-Müllerian hormone; IGF, insulin-like growth hormone
control group, and HBV+ vs. control group, respectively.
a Mann-Whitney U test.
b Chi-square test.(Table 1).Hormone assays
Serum levels of hormones in the HCV+, HBV+, and control
groups are reported in Table 2. The HCV+ and HBV+ groups
had similar AMH levels (p = 0.673, Table 2 and Fig. 1A), which
were lower than those of the control group (p = 0.011 and p =
0.009, respectively). This was particularly evident in the sub-
group of women of full reproductive age (20–30 yr; Table 2).
Moreover, women who were HCV+ were more likely to have
menopausal AMH levels (<0.16 ng/ml) than women who were
HBV+ (OR 11.625; 95% CI 2.651–50.970; p <0.0001) or controls
(OR 5.26; 95% CI 2.169–12.820; p <0.0001). No significant differ-
ence in menopausal AMH levels was present between women
who were HBV+ and controls (OR 0.812; 95% CI 0.090–2.267;
p = 0.981; Fig. 1B). There was no significant difference in 17b-
oestradiol levels among the three groups.
A significant correlation was found between AMH level and
hepatic grade (p = 0.041) or stage (p = 0.038) in women who
were HCV+ but not in those who were HBV+ (p = 0.640 and p
= 0.974, respectively).
Reproductive characteristics
No significant differences in parity or age at first pregnancy
were observed between women who were HCV+ and those
who were HBV+ (Table 2).
In women who were HCV+, occurrence of miscarriages was
significantly related with the median AMH level (1.0 ng/ml;
OR 2.333; 95% CI 1.029–5.292; p = 0.043). No significant rela-
36 Journal of Hepatologygroup (n =
50)
Control group (n =
100)
p, I vs. II p, I vs. III p, II vs. III
1.9 ± 0.9 2.5 ± 1.9 0.673 0.011 0.009
2.4 ± 0.9 4.4 ± 3.2 0.684 <0.0001 <0.0001
2 (4) 4 (4) <0.0001 <0.0001 0.981
87 ± 33 65 ± 50 0.219 0.410 0.882
126 ± 60 n.a. 0.145 -– –
21 (42) n.a. 0.248 – –
27 ± 7 n.a. 0.235 – –
8 (24) 32 (32) 0.0005 0.042 0.020
1 (2) 7 (7) 0.144 0.788 0.196
I vs. II, I vs. III, and II vs. III indicate the p values for HCV+ vs. HBV+ group, HCV+ vs.
AMH levels
Normal<0.16 ng/ml
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Fig. 1. Levels of AMH in the serum of women who were HCV+, HBV+, or
controls. (A) Mean serum levels (bars represent SD and bold lines inside the
box plot median levels). Levels of significance: *p = 0.011; ^p = 0.009 (Mann–
Whitney U-test). (B) Distributions of normal and menopausal serum levels of
AMH among women in the HCV+, HBV+, and control groups. A significant
difference was present between women who were HCV+ vs. those who were
HBV+ () or controls (). Levels of significance: ,: p <0.0001 (Chi-squaretionship between occurrence of miscarriage and HCV genotype
was found (p = 0.947). Eight women who were HCV + reported
multiple miscarriages. Among those who were HBV+, miscar-
riages were rare and not significantly related with median
AMH level (OR 1.55; 95% CI 0.200–12.053; p = 0.672). Only
one woman who was HBV+ had had multiple miscarriages. No
relationship was found in controls between AMH levels and risk
of miscarriage (OR 1.71; 95% CI 0.746–3.961; p = 0.203).
In the cohort of women who were HCV+, at univariate anal-
ysis, age (OR 1.084; 95% CI 1.021–1.151; p = 0.008) and AMH
levels (OR 2.414; 95% CI 1.020–5.713; p = 0.045) were related
with miscarriage risk. At multivariate analysis, only age was
independently related with miscarriage risk (OR 1.082; 95% CI
1.019–1.149; p = 0.010).
Univariate regression analysis of the HCV and HBV cohorts
showed that HCV infection (OR 10.580; 95% CI 3.531–31.700;
p <0.0001), age (OR 1.071; 95% CI 1.018–1.127; p = 0.008), grade
at histology (OR 0.694; 95% CI 0.492–0.977; p = 0.037), and
median AMH levels (OR 4.485; 95% CI 2.141–9.394; p <0.0001)
test). AMH, anti-Müllerian hormone.
2018 vol. 68 j 33–41
were significantly related with risk of miscarriage. At multivari-
ate analysis, only HCV etiology was independently associated
with risk of miscarriage (OR 6.905; 95% CI 1.771–26.926; p =
0.005). When controls were tested against women with HCV
or HBV, at univariate analysis, only the presence of HCV infec-
tion (OR 7.360; 95% CI 2.416–22.420; p <0.0001) and lower
AMH levels (OR 2.242; 95% CI 0.981–5.127; p = 0.056) were
related with risk of miscarriage. At multivariate analysis, HCV
infection alone (OR 9.363; 95% CI 2.569–34.123; p <0.001) was
significantly associated with miscarriage.
AMH levels and response to antiviral therapy
After a diagnosis of HCV infection, 75 women received antiviral
JOURNAL 
OF HEPATOLOGYtreatment with pegylated (IFN) plus ribavirin, combined in
some cases with telaprevir (two patients) or boceprevir (six
patients). Mean age at therapy was 36 ± 8 years. Sustained viro-
logic response (SVR) was achieved in 53 women (70.6%). The
rate of SVR was lower in women with menopausal AMH levels
(10/19, 52.6%) compared with those with normal levels
(44/56, 78.6%) (OR 3.300; 95% CI 1.094–9.952, p = 0.030).
Regression analysis revealed that independent factors for non-
response to treatment were HCV genotype 1 (OR 2.309; 95%
CI 1.119–1.190; p = 0.023) and lower AMH levels (OR 3.649;
95% CI 1.123–11.904; p = 0.031).
AMH levels remained stable in women who achieved SVR
(before therapy: 2.8 ± 2.6 ng/ml; after therapy: 1.8 ± 1.7 ng/ml;
Cp = 0.103). In women who experienced failure of antiviral ther-
apy, AMH levels continued to decrease after failure (baseline: 3.
4 ± 2.7 ng/ml; after therapy: 2.0 ± 1.8 ng/ml; p <0.0001).
Women who achieved SVR had a lower miscarriage rate (17
miscarriages in 53 pregnancies 32.07%) than women who failed
antiviral therapy (14 miscarriages in 22 pregnancies, 63.6%) (OR
0.255; 95% CI 0.090–0.723; p = 0.010).
IGF-1 levels
Mean IGF-1 levels were similar in women who were either HCV
+ or HBV + women (110 ± 58 ng/ml vs. 118 ± 57 ng/ml; p =
0.493). No significant correlation was observed with hepatic
grade (p = 0.461), fibrosis stage (p = 0.697), or liver stiffness (p
= 0.666) (Fig. 2). A positive correlation between AMH and IGF-
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Journal of Hepatology1 levels was observed in women who were HCV+ (p = 0.004),
but not in women who were HBV+ (p = 0.127) (Fig. 2).
Data from the PITER-HCV cohort
The PITER-HCV cohort was recruited in 2014. Since then, a total
of 7,496 patients who are HCV+ (3,317 women) have been
enrolled (Appendix Table 1). Data on parity were available in
1,998 women. Overall, 1,667 pregnancies had been registered.
TFR for the 590 women who were HCV+ and between 18 and
49 years of age was 0.7, compared with 1.37 for the whole Ital-
ian population of the same age range (data from Istat for the
year 2014).11 Among the 650 women who were HCV+ and for
whom miscarriage data were available, 273 (42.0%) had a his-
tory of miscarriage; 122 of whom (44.6%) had a history of mul-
tiple miscarriages [71 women (26.0%) had had two miscarriages,
26 women (0.9%) had had three miscarriages, five women (1.8%)
had had four miscarriages, four women (1.4%) had had five mis-
carriages, two women (0.7%) had had six miscarriages, two
women (0.7%) had had seven miscarriages, and one woman
(0.36%) had had eight miscarriages].
Carriers of HCV genotype 1 had a lower risk of miscarriage
compared with carriers of all other genotypes (OR 0.62; 95%
CI 0.438–0.882, p = 0.007). When HCV genotypes 1 and 2 were
combined, they had a lower OR of miscarriage than the combi-
nation of genotypes 3 and 4 (OR 0.464; 95% CI 0.271–0.794; p =
0.005; Table 3). History of miscarriage was not associated with
fibrosis stage (F3–F4 vs. F0–F2; OR 0.969; p = 0.855), BMI (<25
kg/m2 vs. >25 kg/m2; OR 0.827; p = 0.145), presence of cirrhosis
(present vs. absent, OR 0.961; p = 0.766), diabetes (present vs.
absent; OR 1.20; p = 0.392), hypertension (present vs. absent;
OR 0.852; p = 0.333), history of past and/or present drug addic-
tion (present vs. absent; OR 0.784; p = 0.382) or employment
status (employed vs. unemployed; OR 0.752; p = 0.142).
Analysis of US sample
A total of 27,525 women were identified in the analysis of infer-
tility (20,415 HCV and HIVnegative; 6,805 HCV+; and 305
HCV+/HIV+). Women with HCV had a significantly higher prob-
ability of infertility compared with those who were HCV free
(OR 2.439; 95% CI 2.130–2.794). Moreover, this risk was even
higher among women co-infected with HIV/HCV compared to
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the reported rates in the PITER cohort analysed in this study.
These results point to a specific relationship between HCV infec-
children at rates similar to the general population.
The mechanisms underlying this unfavourable outcome are
most women who smoked or drank alcohol before their diag-
nosis stopped completely. Other possible sociodemographic
a
fr
ng
Research Article Viral Hepatitisthose who were HCV/HIV– (OR 3.635; 95% CI 2.467–5.357).
Among the 13,475 women included in the analysis of pregnancy
outcomes, women with HCV were significantly more likely to
report premature birth (OR 1.336; 95% CI 1.059–1.685) and ges-
tational diabetes (OR 1.240; 95% CI 1.019–1.510), and signifi-
cantly less likely to report live birth (OR 0.754; 95% CI 0.622–
0.913). Risks of stillbirth (OR 1.252; 95% CI 0.491–3.188), pre-
eclampsia (OR 1.206; 95% CI 0.935–1.556) and miscarriage
(OR 1.106; 95% CI 0.885–1.383) were also greater among
women with HCV; however, the ORs were not statistically dif-
ferent (Table 4).
Discussion
Several recent studies have reported a significant relationship
between HCV infection and female reproductive status, high-
lighting the protective effect of a fertile hormonal status on
the progression of fibrosis1,3 and the response to antiviral ther-
apy.2,5 Conversely, during the period around or immediately
after menopause, rapid and unfavourable evolution of both con-
ditions is observed.2,3 The data reported here highlight that the
relationship between HCV infection and reproductive status in
women is deeper and broader than previously thought, with
profound consequences for reproductive function confirmed in
cohorts from different countries. Specifically, we found that Ital-
ian women who were HCV+ had significantly lower levels of
AMH than age-matched uninfected controls or women with
HBV+ and CLD, and this was significantly associated with a
higher miscarriage rate. In a different cohort of women with
HCV in the USA, infertility and premature birth were also signif-
icantly higher and the rate of live birth without complications
significantly lower than among women who were HCV.
Table 3. Risk of miscarriage for women with different HCV genotypes in
the PITER-HCV cohort.a
Comparison OR (95% CI) p
Genotype 1 vs. all others 0.6225 (0.4389–0.8828) 0.007
Genotype 1 + 2 vs. 3 + 4 0.4647 (0.2719–0.7941 0.005
Genotype 1 vs. 2 1.2688 (0.8347–1.9284) 0.265
Genotype 1 vs. 3 0.6163 (0.3136–1.2108) 0.160
Genotype 1 vs. 4 0.3412 (0.1440–0.8084) 0.014
Genotype 2 vs. 3 0.4857 (0.2305–1.0233) 0.057
Genotype 2 vs. 4 0.2689 (0.1073–0.6737) 0.005
Genotype 3 vs. 4 0.5536 (0.1918–1.598) 0.274
Data in bold indicate statistically significant p value (<0.05).
a Adjusted odds ratios (ORs) and 95% CIs were estimated using logistic regressions.
Table 4. Risk of infertility and pregnancy outcomes for women in the US s
Outcomes
Adjusted odds ratio of infertility for women with HCV, HIV/HCV vs. HCV/HIV
Infertility (HCV vs. no HCV)
Infertility (HIV/HCV vs. no HCV/HIV)
Adjusted odds ratio of pregnancy outcomes for women with HCV vs. HCV free
Premature birth
Live birth
Stillbirth
Gestational diabetes
Pre-eclampsia
Miscarriage
a Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated usi
b p <0.05.38 Journal of HepatologyLevels of AMH, which is produced by cells of the developing
ovarian follicles, begin to decline approximately one year before
follicle-stimulating hormone levels increase.6–8 Thus, the AMH
level represents an early and sensitive marker of a woman’s
reproductive potential, with declining levels being a reliable
indicator of ovarian senescence.7 We found that AMH levels
were significantly lower in women who were HCV+ than in
age-matched healthy controls. Such a difference persisted even
when we restricted the analysis to the age range of greatest fer-
tility (20–30 years; Table 2). In addition, women who were HBV
+ had AMH levels that were lower than controls and similar to
those of women who were HCV+. However, the latter had
AMH levels in the menopausal range (<0.16 ng/ml) more often
than age-matched women with HBV+ and CLD of similar
(although moderate) severity, or controls, indicating more-
impaired overall ovarian function.
A key result of our study concerns the association between
HCV infection and risk of miscarriage. In Italy, women with
HCV+ enrolled in PITER had an excessively high miscarriage
rate. Regardless of age, compared with the general Italian pop-
ulation,16 women who were HCV+ and enrolled in our study
had an excessively high miscarriage rate and an unfavourable
ratio between pregnancy attempts and completed pregnancies
compared with uninfected controls or women with HBV. A
higher rate of miscarriage in women with HBV was recently
reported in a prospective Chinese cohort (513 asymptomatic
HBV carriers and 20,491 non-HBV controls22). However, the
percentage reported (9.36% vs. 5.70%; p <0.001) was lower thantion, ovarian function, and reproductive efficiency, suggesting
that the premature ovarian senescence observed in women
who are HCV+, as indicated by the early and significant AMH
decline, has a profound effect on reproductive function. No
apparent relationship was found with a lower desire for preg-
nancy among women with HCV. Accordingly, a recent study
showed that female patients with chronic viral illnesses desire
23not clear. Possible, although not confirmed, maternal risk fac-
tors for miscarriage, such as cigarette smoking or alcohol con-
sumption24–27 were rare in these women and similarly
distributed between those who were HCV+ or HBV+. Further-
more, after being diagnosed with hepatitis virus infection,mple.a
OR 95% CI
ee
2.439b (2.130–2.794)
3.635b (2.467–5.357)
1.336b (1.059–1.685)
0.754b (0.624–0.913)
1.252 (0.491–3.188)
1.240b (1.019–1.510)
1.206 (0.935–1.556)
1.106 (0.885–1.383)
logistic regressions.2018 vol. 68 j 33–41
JOURNAL 
OF HEPATOLOGYfactors, such as history of drug addiction, unemployment, or
lack of health coverage, were not independently related with
miscarriage risk in the Italian cohorts and were rare or not
represented in the US cohort (the latter is derived from a data-
base of commercially insured patients, who are highly unlikely
to be unemployed, to have unstable housing, or to use drugs,
because a drug screen is frequently a prerequisite for employ-
ment). Hence, although we agree that factors such as a history
of drug abuse, unstable housing, or lack of access to healthcare
can be important determinants of fertility and pregnancy out-
comes, our analysis showed that HCV impacts these outcomes
even in a commercially insured population, where such factors
are unlikely to occur, or in women with universal health
coverage.CLD could be another possible cause of impaired ovarian
function. The liver synthesises IGF-1, which is the most potent
trophic ovarian factor, and abnormal liver function could affect
its synthesis.28–30 However, in our prospective clinical cohort,
liver damage, assessed by histology and liver stiffness, was gen-
erally mild and, therefore, would not affect liver synthetic func-
tion. Moreover, in the large PITER-HCV cohort, which included
subjects with all stages of liver disease, no relationship was
observed between severity of CLD (as evaluated by histology
and/or liver stiffness) and history of miscarriages.
Several published data, especially from in vitro fertilisation
(IVF) studies, support the central role of AMH as a predictor of
fertility. Very low AMH levels correlate with a poor response
to stimulation by exogenous gonadotropins and with a lower
implant success rate in IVF.31–36 Some studies indicate that
women who are HCV+ exhibit poor ovarian response to exoge-
nous stimulation and have high rates of complication, poten-
tially favouring miscarriage.34,35 In particular, women who are
HCV+ display reduced rates of ovarian follicle development after
stimulation, higher incidence of apoptosis, and reduced preg-
nancy rates compared with controls.35–37 These findings indi-
rectly confirm our results. Although in our study, women who
were HBV+ had similar mean AMH levels compared with those
who were HCV+, the latter had AMH levels in the menopausal
range significantly more often compared with the former. Fur-
thermore, a significant direct correlation between IGF-1 and
AMH levels and an increased occurrence of miscarriages was
observed only in women who were HCV+. Taken together, these
findings suggest that the reduced reproductive capacity of
women who are HCV+ is related to failing ovarian function
and subsequent follicular depletion occurring in the context of
a more generalised dysregulation of other fertility-related fac-
tors. Among them, the direct involvement of reproductive tis-
sues in HCV infection should not be overlooked. HCV infects
and alters the cellular ultrastructure of trophoblasts, the main
cell type in placenta. The resulting functional impairment of
the trophoblasts and placenta could, in turn, lead to miscar-
riage.38 There are also reports of structural abnormalities of
the reproductive tissues in women with HCV+, which could con-
tribute to the high risk of miscarriage.39,40
Pathogenic mechanisms could involve both a direct effect of
HCV infection, because of the infection of reproductive tissues,39
and an indirect effect, because of the oxidative stress induced by
HCV infection.41 Data from the PITER-HCV cohort showed that
women infected with HCV genotypes 3 and 4 (which are associ-
ated with higher levels of oxidative stress compared with other
genotypes) were at higher risk of miscarriage than women car-
rying other genotypes. A recent meta-analysis, including 5,218Journal of Hepatologypregnant women with HCV, suggested that HCV infection is sig-
nificantly associated with a higher risk of preterm birth,42 which
is consistent with the premature birth risk observed in our US
sample. These findings suggest that the reproductive system is
another extrahepatic target for HCV and is involved in the pro-
found and broad physiological dysregulation induced by HCV
itself.43 Indeed, existing data indicate that HCV infection is also
associated with male seminal abnormalities, such as altered
sperm morphology and decreased semen volume, sperm count,
and progressive sperm motility.44,45
A limitation of this study was that the women were not
enrolled in a predefined treatment protocol but were treated
according to physicians’ choice and the therapies used were
all IFN based. However, women who achieved SVR had a signif-
icantly lower miscarriage rate than women who failed antiviral
therapy. Furthermore, AMH continued to decline in non-
responders and remained stable over time in women achieving
SVR.
In conclusion, our observation of decreased fertility and
poorer pregnancy outcomes among women who are HCV+
allows us to conclude that having HCV infection significantly
and negatively affects many aspects of fertility. It remains to
be assessed whether antiviral therapy at a very early age can
positively influence the occurrence of miscarriages and can pre-
vent ovarian senescence, because the latter has broader health
implications than simply preserving fertility. Therefore, the
effect of treatment with new-generation antiviral drugs could
be assessed prospectively with this dual purpose.
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